Following in the footsteps of the other review programs at the US Food and Drug Administration's (FDA) Office of Pharmaceutical Science, the Office of Biotechnology Products (OBP) is currently in the ...
As the country looks to commercial companies to drive innovation, it has a golden opportunity to support open science and increase its output in key areas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results